← Back to Biotech Intelligence
DRUG OBJECT · cand_cfa47cb9-7f6e-5bb7-b0a1-a10e19345ced

cand_cfa47cb9-7f6e-5bb7-b0a1-a10e19345ced

Positive Topline Results from a Phase 3 Trial for VGX-3100 in Cervical Dysplasia Patients Announced by ApolloBio, INOVIO's Partner in China

cervical dysplasia

Eventsevt_0cea90ad-76d8-5292-b5a0-c93d3133d7ca
Evidenceevd_218c7983-65a9-5b2e-8e98-d80642b609ba, evd_25115e3e-41ab-5905-8f8d-469c3cf8328e, evd_5e227ab9-5de4-5c0c-90d8-33572dff1091, evd_6bf2e8a9-57d4-5dc4-9e69-5b696b1b8a79, evd_7acac3c5-713b-51b7-8de9-97654dd4a784, evd_96df8254-ab7c-56d6-acf1-283c14a86b8e, evd_b2fae743-6d27-5e23-beb0-402936263e64
Factsfact_41f1ce0c-0258-53c9-93a8-a036659aea61, fact_a4e36971-d899-5004-b1bf-5794e0df3212
Relationsrel_171927fb-9b39-5dda-a8b5-898ecade4edd, rel_4138ae80-bb07-51a1-9b44-22be678e7364, rel_5fbe6978-6334-5954-ae4c-dd2a1b2f3f06, rel_8629123a-2bde-5e29-a72d-4dfd04423e54

Sources